A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Record History

See every version on ClinicalTrials.gov ↗

1. Notable Oct 6, 2021 Primary endpoint revised

   • Secondary endpoints: 6 to 2
   • Study description expanded, about 2 words

   v7
2. Minor Sep 14, 2021 Study completion date: Jun 30, 2021 to Jun 30, 2022v6
3. Minor Sep 1, 2020 Primary completion date changed from estimate of Jun 30, 2020 to Aug 9, 2020

   • Study completion date: Jul 31, 2020 to Jun 30, 2021

   v5
4. Minor Jul 10, 2019 Trial status: Enrolling by Invitation to Active, Not Recruiting

   • Enrollment target: estimated 15 to confirmed 19

   v4
5. Minor Nov 27, 2018 Study sites: 1 to 2v3
6. Notable Nov 6, 2018 Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less

   • Primary completion date: Sep 30, 2018 to Jun 30, 2020
   • Start date changed from estimate of Jul 1, 2018 to Nov 5, 2018
   • Study sites: 0 to 1
   • Study completion date: Dec 31, 2019 to Jul 31, 2020
7. Minor Jun 25, 2018 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.